Basic Information

Strain Name
C57BL/6-Pdcd1tm1(PDCD1) Tnfrsf18tm1(TNFRSF18)/Bcgen
Stock Number
120528
Common Name
B-hPD-1/hGITR mice
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
Pd-1 (Programmed death-1);Tnfrsf18 (tumor necrosis factor receptor superfamily, member 18)
Species
C57BL/6
Appearance
Black
Genotypes
Homozygous
NCBI Gene ID

Protein expression analysis

Species-specific PD-1 protein expression analysis in wild-type and humanized B-hPD-1/hGITR mice. Splenocytes were isolated from both wild-type C57BL/6 (+/+) and homozygous B-hPD-1/hGITR (H/H) mice and analyzed by flow cytometry using species-specific anti-PD-1 antibodies. Mouse PD-1 protein was detected in wild-type mice, while human PD-1 protein was detected in B-hPD-1/hGITR mice.

Species-specific GITR protein expression analysis in wild-type and humanized B-hPD-1/hGITR mice. Splenocytes were isolated from both wild-type C57BL/6 (+/+) and homozygous B-hPD-1/hGITR (H/H) mice and analyzed by flow cytometry using species-specific anti-GITR antibodies. Mouse GITR protein was detected in wild-type mice, while human GITR protein was detected in B-hPD-1/hGITR mice.

Spleen immune cell analysis

Analysis of spleen leukocytes in humanized B-hPD-1/hGITR mice. Splenocytes were isolated from wild-type C57BL/6 and humanized B-hPD-1/hGITR mice (n=3). The proportion of leukocytes subpopulation was tested by flow cytometry. As a result, the expression profile of leukocytes subpopulation in homozygous B-hPD-1/hGITR mice is similar to that in the C57BL/6 mice, indicating that differentiation of T cells, B cells, NK cells, monocytes, DC cells and macrophage cells are not affected by the humanization of hPD-1/hGITR.

Blood tests

Blood Routine Test. Blood from wild-type C57BL/6 and B-hPD-1/hGITR mice (n=3) was collected and analyzed by blood routine test. As a result, there is no significant differences between wild-type and B-hPD-1/hGITR mice.

Blood chemistry tests of B-hPD-1/hGITR mice. Serum from the C57BL/6 and B-hPD-1/hGITR mice was analyzed for the levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). There was no differences on either measurement between C57BL/6 and B-hPD-1/hGITR mice, indicating that introduction of hPD-1 and hGITR in place of its mouse counterpart does not change ALT and AST levels. Values are expressed as mean ± SEM.

Combination therapy in B-hPD-1/hGITR mice

Antitumor activity of anti-GITR antibody INCAGN01876 combined with anti-hPD-1 antibody pembrolizumab in B-hPD-1/hGITR mice. (A) Anti-hGITR antibody INCAGN01876 (in house) combined with anti-hPD-1 antibodies pembrolizumab inhibited MC38-hPD-L1 tumor growth in B-hPD-1/hGITR mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hGITR mice (female, 7 week-old, n=5). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with antibody INCAGN01876 combined with anti-hPD-1 antibody pembrolizumab with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hGITR and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hGITR mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hGITR antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.

Antitumor activity of anti-GITR antibody BMS-28F3 combined with anti-hPD-1 antibody pembrolizumab in B-hPD-1/hGITR mice. (A) Anti-hGITR antibody BMS-28F3 (in house) combined with anti-hPD-1 antibodies pembrolizumab inhibited MC38-hPD-L1 tumor growth in B-hPD-1/hGITR mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hGITR mice (female, 7 week-old, n=5). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with antibody BMS-28F3 (in house) combined with anti-hPD-1 antibody pembrolizumab with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hGITR and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hGITR mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hGITR antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.

Related products

B-hGITR mice

B-hPD-1 mice

B-hPD-1/hPD-L1/hGITR mice

 

 

Back to top